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Background: There are many societal and cultural differences between healthcare sys-
tems and the use of genetic testing in the US and France. These differences may affect
the diagnostic process for autism spectrum disorder (ASD) in each country and influence
parental opinions regarding the use of genetic screening tools for ASD.
Methods: Using an internet-based tool, a survey of parents with at least one child with
ASD was conducted. A total of 162 participants from the US completed an English version
of the survey and 469 participants from France completed a French version of the survey.
Respondents were mainly females (90%) and biological parents (94.3% in the US and
97.2% in France).
Results:The mean age of ASD diagnosis reported was not significantly different between
France (57.5±38.4 months) and the US (56.5±52.7 months) (p=0.82) despite significant
difference in the average age at which a difference in development was first suspected
[29.7 months (±28.4) vs. 21.4 months (±18.1), respectively, p=7×10−4]. Only 27.8% of
US participants indicated that their child diagnosed with ASD had undergone diagnostic
genetic testing, whereas 61.7% of the French participants indicated this was the case
(p=2.7×10−12). In both countries, the majority of respondents (69.3% and 80% from
France and the US, respectively) indicated high interest in the use of a genetic screening
test for autism.
Conclusion: Parents from France and the US report a persistent delay between the initial
suspicion of a difference in development and the diagnosis of ASD. Significantly fewer
US participants underwent genetic testing although this result should be regarded as
exploratory given the limitations. The significance of these between country differences
will be discussed.
Keywords: autism spectrum disorders, survey, parents’ opinion, genetics, France, US
BACKGROUND
Autism spectrum disorders (ASDs) are a group of highly herita-
ble developmental disorders characterized by early impairments
in communication and social interaction, and restricted inter-
ests, and repetitive behaviors (1, 2). Recent reports estimate the
median prevalence rate to be 62/10,000 (3) but there is clear evi-
dence that rates have increased over time. In the US, the CDC
estimates that the prevalence of ASD is approximately 1 in 88
children (4). In France, the most recent epidemiological survey
confirmed this increase and found a prevalence rate among 8 year
olds of 33.5/10,000 (5).
In terms of treatment, a combination of developmental
and behavioral approaches is now recommended focusing on
early, intensive intervention and parental collaboration (6).
Recently, several meta-analyses were published suggesting that
comprehensive early intensive behavioral interventions programs
lead to positive effects regarding intellectual functioning, language
skill, and adaptive behavior outcome (7–10). However, there were
many differences between meta-analyses and potential confounds
and limitations that might have lead to discrepant findings across
these studies (11). The only randomized controlled trial of an early
intensive behavioral intervention [the early start Denver model
(ESDM)] demonstrated significant gains in visual processing and
improvements in language abilities, with subsequent gains in intel-
lectual quotient and adaptive behaviors, among children receiving
the ESDM (6). Moreover, a secondary outcome measurement from
this trial suggested that ESDM is associated with normalized brain
activity patterns related to social attention and engagement, and
that these normalized brain activity patterns are correlated with
improvements in social behavior (12).
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Despite an increase in ASD research in recent years, there con-
tinues to be much debate on autism leading to extensive media
coverage (13). For example, between psychiatric care and educa-
tional and behavioral methods (14), between parent’s advocacy
groups and associations of individuals with autism (15), and
between media presentation of research advances and evidence-
based data per se (16). Among the many issues debated, much
focus has been given to early diagnosis and the contribution of
genetic factors to the cause of autism. Although the importance
of early diagnosis and treatment of autism is well accepted, the
methods used to achieve early diagnosis are debated (17). To date,
specific clinical screening instruments do not show high sensi-
tivity despite acceptable specificity (18). Delays in diagnosis are
not only due to a shortage of accessible specialists, but also due
to clinical and developmental limitations regarding infant/toddler
assessment tools (19). In many instances, parents’ initial concerns
regarding their child’s development are not specific to autism and
may be associated with many other conditions in the differential
diagnosis (20). Moreover, some clinicians consider that sharing a
possible diagnosis of ASD with parents may alter the way these
parents will interact with their child as shown in siblings at-risk of
ASD (21). Finally, the cost of general population screening is also a
concern in countries that do not have free access to healthcare. The
use of family history (one or more older siblings with ASD) (22) or
perinatal factors (e.g., prematurity) (23) has been suggested as an
alternative method to general population screening in identifying
children at-risk for ASD.
In regard to genetic risk for ASD, the majority of research has
consistently shown that ASDs have a strong genetic component
with heritability rates ranging from 60 to 80% (24, 25) and close
to 40% in the largest recent twin study (26). Therefore, there is
little doubt of the importance of genetic factors in autism (27–
29). However, most authors agree that the number of ASD cases
explained by a single genetic abnormality is limited to approxi-
mately 15–20%. These include single gene mutations (e.g., Fragile
X syndrome) or copy number variants (CNVs) (e.g., at 15q11–q13
locus). Although other causal factors (e.g., pre-, peri-, post-natal
factors) have been studied in autism (20, 30), interest in the media
and in high-impact scientific journals has been limited (31). Yet,
they may account for some part in the recent increase in preva-
lence rate (32). As a result, the majority of cases of autism are often
described as a combination of (1) rare genetic variants with high
effect size, (2) common genetic variants with low effect size, and (3)
environmental (or non-genetic) risk factors (29, 31, 33). A recent
study addressed the challenges of early diagnosis and use of genetic
risk factors by reviewing the research related to biomarkers associ-
ated with ASD (16). The authors recognized the widespread hope
that the discovery of valid biomarkers for autism will enable earlier
diagnosis and treatment. However, careful review of the literature
shows major scientific challenges and ethical concerns related to
the development of biomarkers and their clinical application (16).
In addition, societal and cultural attitudes and practices may
also contribute to differing opinions regarding ASD as seen with
other neurodevelopmental conditions. For example, there is con-
siderable controversy regarding the use of medications in children
(34) or the diagnosis of pediatric bipolar disorder (35) despite sim-
ilar national recommendations in the US and Europe. Healthcare
systems are also very different in Europe and the US, which may
influence both expectations and access to care. Finally, regulations
related to genetic testing and societal acceptance of genetic con-
tributions to ASD may differ drastically influencing both standard
of care and patients’ willingness to undergo genetic testing.
To investigate the impact of societal and cultural differences in
the approach to health care and autism on the diagnostic expe-
rience and parental attitudes regarding genetic risk assessment
testing for autism, we conducted two parallel web surveys in the US
(36) and France. These countries were chosen due to their cultural
and social contrasts regarding both healthcare systems and genetic
testing regulations (Table 1). The French healthcare system com-
bines universal coverage with a public–private mix of hospital and
ambulatory care, whereas the US healthcare system depends on
private, for-profit health insurance. Although France has a higher
volume of service provisions than the US (37), millions of Amer-
icans have inadequate or limited access to care because they have
inadequate or no health insurance. Data from the 2011 National
Health Interview Survey (NHIS) show that the percentage of per-
son uninsured at the time of interview was 15.1% (46.3 million) for
persons of all ages and 7% (5.2 million) for children below 8 years
(38). Regarding early developmental risk, both the US and French
pediatric associations recommend careful early follow-up and sys-
tematic examinations during the first 2 years of life to screen for
early-onset condition and disabilities. However, only a few states in
the US support specific programs for low-income families,whereas
in France, these examinations are supported by two parallel reg-
ulations: (1) seven free medical examinations during pregnancy1
and 20 pediatric free examinations during the first 6 years (Code
of Public Health – article L.2132-2); (2) free access “dispensaries”
funded by the Protection Materno-Infantile program located in
all areas that offer medico-social action to promote maternal and
child health (Code of Public Health – article R2112-1 to R.2112-8).
When a diagnosis of autism is suspected, the child can be referred
to local mental health ambulatory services and/or to the Regional
Center de Resources for Autism where the diagnosis is confirmed
(39). Again, within the French healthcare system, these services
are free. In the US, first-line primary care services and specialty
clinics for ASD are also available, but access to the services is vari-
able as explained above. In terms of diagnosis classification, the
DSM-IV is the standard in the US, whereas in France, clinicians
use DSM-IV, ICD-10, or CFTMEA. Correspondence algorithms
are available (40).
Similarly, regulations for genetic testing differ in the two coun-
tries. Genetic tests for over 2,000 diseases are currently available
for use in clinical settings in the US. In addition, a growing num-
ber of tests are being developed to look at multiple genes that may
increase or decrease a person’s risk of common diseases. In 2008,
the former Secretary’s Advisory Committee on Genetics, Health
and Society of the US Department of Health and Human Ser-
vices released a report identifying gaps in the regulation, oversight,
and usefulness of genetic testing. However, few recommendations
have been addressed2. In France, regulations are more stringent.
1http://www.ameli.fr/professionnels-de-sante/sages-femmes/
exercer-au-quotidien/formalites/la-maternite.php
2http://www.cdc.gov/genomics/gtesting/index.htm
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Table 1 | A brief overview of the use of genetic testing in the US and France.
U.S. France
GENERAL CONTEXT
Health care system insurance No universal coverage Universal coverage
Mainly private services, for-profit health insurance Mix of private and public services
Access to genetic testing Few recommendations Governed by law
Variable insurance coverage Fully covered
SPECIFIC CONTEXT OF ASD
Classification for ASD DSM-IV DSM-IV, ICD-10, CFTMEA
Diagnosis Occurs mainly in private settings Occurs mainly through free and prepaid public services for child
early development (pediatrician) and mental health including public
clinics for autism
Treatment setting Mainly private, and through special education Mix of public health, private non-profit care and special education
Recommended genetic testing High-resolution karyotype study High-resolution karyotype study
Fragile X Fragile X
Genetic diagnostic test Numerous chromosomal microarray tests No genetic diagnostic test available
Numerous sequencing tests for ASD
Genetic screening tests for ASD One genetic screening test for siblings No genetic screening test available
Only DNA analyses for medical, legal, or scientific purposes are
authorized by law, and the numerous predictive genetic analyses
being developed and available online are raising ethical and legal
questions (41).
Regarding ASD, the clinical genetic tests currently available
are limited to diagnostic use and serve to identify the underly-
ing genetic etiology of a child already diagnosed with an ASD.
They include chromosomal microarray, Fragile X analysis, and
tests for known genetic syndromes associated with ASD. In the
US and France, it is recommended that a child diagnosed with
ASD undergo high-resolution karyotype studies and Fragile X test-
ing (42, 43). Clinical chromosome microarray tests are commonly
available in the US through medical prescription, but insurance
reimbursement for such testing is variable. In France, chromoso-
mal microarray analyses are also commonly available. Reimburse-
ment is systematic after medical prescription. Recently, based on
studies showing the combined effect of common single nucleotide
polymorphisms (SNPs) on ASD susceptibility (44), an SNP-based
DNA test has become available in the U.S which assesses the risk
of ASD in children who have an older sibling diagnosed with
ASD (ARISk Test; IntegraGen, Cambridge, MA, USA). This test is
also only available through a medical prescription by a qualified,
licensed, medical professional.
In summary, the aim of this study was to compare the diag-
nostic experience with ASD, access to genetic testing and parental
attitudes regarding the use of a genetic risk assessment tool to aid
in the earlier diagnosis of ASD between France and US families
considering the differences in healthcare models, genetic testing
regulations and early screening and diagnostic practices for ASD
between the two countries. To our knowledge, no similar study
comparing France and US population samples has been published
previously.
MATERIALS AND METHODS
POPULATION
Two self-administered internet-based surveys were administered
consecutively using software available from SurveyMonkey3. The
initial survey was conducted in English only and limited to US res-
idents who were parents or guardians of one or more children with
ASD. Requests for participation were e-mailed to potential partic-
ipants by representatives from local and regional autism advocacy
groups [for more details see Ref. (36)]. Responses to the survey
were collected from February 13, 2012, until March 23, 2012. The
second survey was conducted in French only and was administered
to parents or guardians from France or other French-speaking
countries with one or more children with ASD. Participants were
recruited over a web link posted on the blog “autisme infantile,”4
the Facebook group “handicap et éducation spécialisée,”5 and the
association “Ecolalie.” The survey was conducted from June 27,
2012, until July 9, 2012.
SURVEY DESIGN
The survey was designed to assess parental opinions regarding the
ASD diagnostic process for their child and genetic testing related to
ASD. It consisted of four sections: (1) parental perceptions regard-
ing the ASD diagnostic process related to the respondent’s most
recently diagnosed child. This included questions regarding the
timing of initial suspicion of a difference in development, the
referral process, and age at diagnosis; (2) parental experiences with
genetic testing for their child diagnosed with ASD. This sections
also included questions focused on the perceived role of genetics
3http://www.surveymonkey.com
4http://autismeinfantile.com/
5http://www.facebook.com/groups/chapellier/
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in ASD; (3) for parents who reported having a younger, undiag-
nosed child younger than 48 months, parental opinion regarding
whether they would want to have their younger child receive a
genetic test which assessed the child’s risk of ASD, even if it could
not confirm a diagnosis; (4) demographic data of the respondent
including age, gender, and education level. Participants who did
not have a child with ASD were excluded from the survey. Survey
questions were yes/no, multiple choice answers or 4-point Lik-
ert scale (1 – highly likely; 2 – somewhat likely; 3 – somewhat
unlikely; 4 – not likely). All questions were presented in a fixed
order. Respondents were allowed to change their responses to any
question prior to submitting as “final” the survey, after which no
further changes could be made.
The survey was reviewed and pilot tested with select parents of
children with ASD and with specialists who provide clinical care
and diagnostic services for children with developmental delays
and/or ASD. All surveys were completed anonymously and no
information was collected that permitted the identification of any
individuals completing the survey.
Descriptive statistics included means, medians, ranges, and/or
percentages. Responses from French and US participants were
compared using the χ2 test.
RESULTS
CHARACTERISTICS OF THE SAMPLES
A total of 162 participants completed the US survey and 554 par-
ticipants (469 from France, 40 from Canada, and 45 from other
countries) completed the French survey. For the purpose of this
study, only participants from the US and France were included.
Their characteristics are detailed in Table 2. In both samples, most
of the participants were females (90%). The majority of respon-
ders (97.2 and 94.3% in France and the US, respectively) indicated
that they were biological parents, the remaining were adoptive par-
ents, stepfathers, grandparents, aunts/uncles, or guardians. French
respondents were significantly younger, although more than 40%
of respondents in both groups were between the ages of 36 and
45 years. Approximately 76% of the US respondents and only 55%
of the French respondents had at least a college degree, mean-
ing that socioeconomic status was on average lower in the French
sample.
AGE OF FIRST CONCERN AND AGE OF DIAGNOSIS
We identified a significant difference in the average age at which
a difference in development was first suspected between the two
populations with a mean age of 29.7 months (±28.4) reported
in the French sample and 21.4 months (±18.1) reported in the
US sample (p= 7× 10−4). However, the mean reported age when
ASD was diagnosed was 57.5 months (±38.4) in the French sam-
ple compared to 56.5 months (±52.7) in the US sample (p= 0.82),
reflecting no statistical difference in the age at diagnosis between
the US and France.
ACCESS TO GENETIC TESTING
Most participants declared that they believed genetic factors con-
tributed to the cause of ASD. Eighty-two percent of the US partici-
pants and 59% of the French participants indicated that ASD was a
combination of genetic and environmental factors. Twelve percent
of US participants and 24% of French participants indicated that
Table 2 | Sample characteristics.
France, N (%) US, N (%) p
GENDER OFTHE RESPONDERS
M 42 (9.3) 16 (11.0) 0.555
F 410 (90.7) 130 (89.0)
AGE OFTHE RESPONDERS
<36 178 (37.0) 33 (23.6) 3×10−8
36–45 202 (42) 58 (41.4)
46–55 45 (9.4) 38 (27.1)
>55 56 (6.9) 11 (7.9)
EDUCATION LEVEL OFTHE RESPONDERS
Less than high school 88 (20.0) 0 (0) 0.004
High school/GED 110 (25.1) 35 (23.5) 0.98
College degree 159 (36.2) 59 (39.6) 0.97
Graduate degree 82 (18.7) 55 (36.9) 0.01
RESPONDERS INVOLVED IN A PARENTS ASSOCIATION
Yes 242 (54.5) 74 (50) 0.34
No 202 (45.5) 74 (50)
REPORTED DIAGNOSIS
Autistic disorder 185 (42.6) 86 (54.9) 0.15
PDD-NOS 209 (48.2) 31 (19.1) 0.71
Asperger syndrome 40 (9.2) 35 (21.6) 0.04
Unknown 35 (7.5) 4 (4.3)
Table 3 | Reported rates of genetic testing performed in affected
individuals.
France, N (%) US, N (%) p
Yes 284 (61.7) 42 (27.8) 3.5×10−13
Genetic testing
recommended but declined
17 (3.7) 12 (7.9) 0.03
No genetic testing
recommended
150 (32.6) 93 (61.6) 1.3×10−10
Don’t know 9 (2.0) 4 (2.7)
ASD was almost entirely a result of genetic factors (p= 0.0005).
However, only 27.8% of US participants indicated that their
child diagnosed with ASD had undergone genetic testing, whereas
61.7% of French participants indicated so (p= 2.7× 10−12)
(Table 3).
RISK OF AUTISM IN THE SIBLING
Twenty-five participants from the US survey and 101 participants
from the French survey reported that their family included a sib-
ling, as of yet not diagnosed with an ASD and under the age of
48 months. Of these, 13 (52%) respondents from the U.S and 48
(47%) respondents from the French survey felt that the younger
sibling was somewhat or highly likely to develop ASD. However,
15 respondents (60%) from the US survey and 58 respondents
(57%) from the French survey indicated that they had a somewhat
or very low level of anxiety regarding the younger sibling’s risk of
ASD. Seventy respondents from the French survey (69.3%) and 20
respondents from the US sample (80%) with a younger undiag-
nosed child,<48 months old, indicated that they would want their
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child tested if a genetic test were available that could identify risk
for ASD, even if it could not confirm or rule out the diagnosis.
DISCUSSION
France and the US differ in many sociocultural aspects such as
healthcare systems and the regulation of genetic testing (Table 1).
These differences may have consequences on early autism diagno-
sis and parental opinions about genetic testing and access to it. In
our study, the mean age of first concern was significantly later in
the French sample than in the US sample. However, our results
are not strictly consistent with previous French studies (45, 46). In
the largest study conducted to date (N = 424), the mean age when
French parents first reported early signs of ASD in their children
was 19 months (±11.7), and 27 months (±17.5) when their chil-
dren were first evaluated by a medical professional (20). However,
in both the US and French samples, the mean reported age of
ASD diagnosis was approximately 57 months. These results coin-
cide with reports in the literature suggesting that children may not
receive a formal diagnosis until the age of 4 (4, 46, 47). Recently,
French parents’ advocacy organizations have claimed that a delay
in diagnosis is still ongoing in France. However, the current results
contradict these claims and are consistent with Chamak et al.’s
(46) recent study, showing that the age of diagnosis of autism has
decreased over the years in France since the beginning of the 1990s
(Figure 1).
With a majority of the participants from France (59%) and
the US (82%) indicating that ASD was a result of the genetics
and non-genetic factors, most of participants’ knowledge in both
countries is in accordance with the state of the art. Significantly
more participants from France (24%) than from the US (12%)
indicated that ASD was almost entirely a result of genetic factors.
This result may be surprising considering the numerous genetic
tests currently available for clinical use in the US. However, this
may reflect the influence in French popular opinion regarding the
role of genetic factors in the origin of autism (13, 15).
A significantly higher number of children diagnosed with ASD
were reported to have undergone clinical genetic testing in the
French sample (60%) compared to the US sample (28%). Despite
the American Academy of Pediatrics suggestion that primary care
physicians should obtain high-resolution chromosome studies
and Fragile X testing when the diagnosis of an ASD is made (48)
and the American College of Medical Genetics recommendation
that a genetic consultation should be offered to all persons and
families with ASD (43), only 28% of the US participants indicated
that their child diagnosed with ASD had undergone genetic testing.
This result may be consistent with Selkirk et al.’s study performed
in the US reporting that only 24% of 255 parents whose children
were diagnosed with an ASD reported seeing a genetic counselor
(49). Similarly, in a recent qualitative study of parents’ experience,
Chen et al. reported that only 28% of 42 parents with at least
one child diagnosed with ASD had reported that their child had
undergone genetic testing. Moreover, 63% of the parents whose
children had not undergone genetic testing for ASD reported that
they had never heard of such testing before the interview (50).
Sixty percent of French respondents indicated that their child
had undergone genetic testing, as recommended since 2005 by the
French Haute Autorité de Santé (HAS). This is in accordance with
FIGURE 1 | Changes in age of ASD diagnosis in France during the last
40 years [extracted from Ref. (46); courtesy of Claude Bursztejn]. *The
dot line indicates that the 2001–2005 result should be regarded with
caution as based on only N =19 cases.
Chamak et al. who reported that 51.5% of the individuals with
ASD in a French sample of 200 families had undergone clinical
genetic testing (personal communication).
With 60% of the parents from the US reporting that no genetic
testing was recommended, the low rate of genetic testing reported
for the children from the US (28%) may be mainly attributed to a
lack of healthcare provider’s referral. This observation is consistent
with previous findings showing the importance of physicians refer-
ral in accessing genetics services for children with ASD (51); ASD,
Down syndrome and/or mental retardation (52); or hearing loss
(53). However, little information is available in the literature about
healthcare provider’s attitudes toward genetic testing. Recently, a
literature review of genetic testing in psychiatry found that not
all psychiatrists felt competent about their genetic knowledge (9–
70%) or ability to offer and interpret genetic test (54). More
recently, a large e-mailed survey explored psychiatrists’ and neu-
rologists’ (mostly with an adult practice) practices and knowledge
concerning genetic testing and found that only 33% of respondents
felt confident about how to order and where to send genetic tests
(55). Almost half of neurologists and over 75% of psychiatrists
were not aware of a genetic counselor or geneticist to whom to
refer patients (55). One may also be questioning physician knowl-
edge about the inheritance of autism: in 2008, nearly half of a small
group of randomly selected psychiatrists were found to rate that
genetics has a“weak influence”or“no influence”on the heritability
of autism (56). Moreover, because evidence-based interventions
for ASD are primarily behavioral, the healthcare provider may not
see the need for genetic testing.
The impact of free access to care may also be a key factor in
determining the frequency with which clinical genetic testing is
used in autism. Considering that (1) higher education, as seen in
the US sample, is related to better genetic knowledge and increased
access to genetic testing (50); and (2) regulations regarding genetic
testing are more stringent in France, a higher rate of genetic
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testing would have been expected in the US sample rather than
the French sample. It is likely that free access to care in France
may in part explain the better accordance with genetic testing
recommendations in ASD found in this country.
This study should be interpreted in the context of its numerous
limitations. First, the comparative survey relied on retrospective
self-reporting data collection from parents with numerous biases
due to recollection. Second, the parents who responded to the
survey may not be representative of the population of families
with ASD in France and in the US since most of the parents were
contacted via advocacy organizations indicating a higher degree
of involvement, and all participants had to have access to a com-
puter. It is probable that the rates reported here are overestimated.
Moreover, it is not possible to determine the response rate for an
internet survey and it is unknown whether respondents differed
in salient ways from non-respondents. For example, families who
do not have regular access to a computer or time to respond a
survey may not be reflected in the survey. Third, internet-based
survey is considered less reliable than direct or e-mail interviews
and does not permit clinical diagnosis confirmation of included
patients. Also, the collection of ethnicity data was not allowed by
the French National Informatics and Liberty Commission (Com-
mission nationale de l’informatique et des libertés, CNIL), therefore
no comparison could be done with the US data. Fourth, survey
participants were not asked to indicate the gender and the age
of the affected child. Considering recent changes in the US and
French guidelines regarding ASD screening and diagnostic prac-
tices, it is unclear whether our results reflect these changes or not,
and as a consequence whether older patients could have skewed
the results. Indeed, most of what we know about genetics and
autism has been learned in the past 20 years. We cannot exclude
that the results from the US sample reflect unavailability of genetic
testing for older patients. However, the percentage of US families
reporting genetic testing in our survey is similar to that found in
two recent studies based on a direct interview (50) and an anony-
mous survey (49). Finally, possible biases due to local variation
of accessibility to genetic testing cannot be adjusted in such an
internet survey as far as anonymity prevented collection of par-
ticipant’s addresses. This may be an issue for the US sample given
that France is no more than a regular US state in terms of surface.
CONCLUSION
Parents from France and the US report a persistent delay between
the initial suspicion of a difference in development and the diagno-
sis of ASD. Age of diagnosis was about 4.5 years in both countries.
Additionally, most parents from both countries with a younger
undiagnosed child reported that they would pursue genetic risk
assessment testing that could identify risk for ASD in a younger
sibling even if it could not confirm or rule out a diagnosis. How-
ever, significantly fewer US participants underwent genetic testing.
We hypothesize that this is the result of economic issues.
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